Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

Some might argue that it's too late for investors to get in on Eli Lilly, while others could feel that its work in the diabetes and obesity markets still makes it an attractive long-term option.

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...

Like many pharma stocks, Eli Lilly (NYSE: LLY ... under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for patients aiming to shed ...

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

Eli Lilly stock has advanced more than 200% over ... commercialized under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. But doctors have prescribed either one for patients ...